Immunosuppressive acidic protein (IAP) serum levels in breast cancer

M. Quaranta, M. Coviello, V. Lorusso, C. Rella, G. Micelli, G. C. Torre

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immunosuppressive acidic protein (IAP) serum levels were determined by single radial immunodiffusion in 180 women with breast cancer, in 33 with benign breast disease and in 66 healthy controls. IAP cut-off value was set at 550 μg/ml (mean for the control group plus 2SD). Higher values were found in 4/48 (8%) women with benign breast disease and in 80/180 (44%) patients (pts) with breast carcinoma considering all stages. In particular, with regard to the stage of disease, elevated IAP levels were observed in 6/50 (12%) pts with negative axillary limphnodes (N-), in 45/95 (47%) pts with positive limphnodes (N+) and in 29/35 (83%) pts with metastatic disease. Among healthy subjects only 2/66 (3%) women showed elevated serum IAP levels. Our preliminary data show that IAP is a reliable tumor marker in advanced breast cancer, therefore it can be useful in monitoring the clinical course of the disease. Moreover it may aid in postoperative follow-up, detecting relapse or metastasis and may be recommended as an addition to diagnostic procedures.

Original languageEnglish
Pages (from-to)191-194
Number of pages4
JournalJournal of Tumor Marker Oncology
Volume5
Issue number2
Publication statusPublished - 1990

Fingerprint

Breast Neoplasms
Serum
Breast Diseases
Immunodiffusion
Tumor Biomarkers
Healthy Volunteers
immunosuppressive acidic protein
Neoplasm Metastasis
Recurrence
Control Groups

ASJC Scopus subject areas

  • Cancer Research

Cite this

Quaranta, M., Coviello, M., Lorusso, V., Rella, C., Micelli, G., & Torre, G. C. (1990). Immunosuppressive acidic protein (IAP) serum levels in breast cancer. Journal of Tumor Marker Oncology, 5(2), 191-194.

Immunosuppressive acidic protein (IAP) serum levels in breast cancer. / Quaranta, M.; Coviello, M.; Lorusso, V.; Rella, C.; Micelli, G.; Torre, G. C.

In: Journal of Tumor Marker Oncology, Vol. 5, No. 2, 1990, p. 191-194.

Research output: Contribution to journalArticle

Quaranta, M, Coviello, M, Lorusso, V, Rella, C, Micelli, G & Torre, GC 1990, 'Immunosuppressive acidic protein (IAP) serum levels in breast cancer', Journal of Tumor Marker Oncology, vol. 5, no. 2, pp. 191-194.
Quaranta M, Coviello M, Lorusso V, Rella C, Micelli G, Torre GC. Immunosuppressive acidic protein (IAP) serum levels in breast cancer. Journal of Tumor Marker Oncology. 1990;5(2):191-194.
Quaranta, M. ; Coviello, M. ; Lorusso, V. ; Rella, C. ; Micelli, G. ; Torre, G. C. / Immunosuppressive acidic protein (IAP) serum levels in breast cancer. In: Journal of Tumor Marker Oncology. 1990 ; Vol. 5, No. 2. pp. 191-194.
@article{792c7d517a9b44ec816cffed0adf9c38,
title = "Immunosuppressive acidic protein (IAP) serum levels in breast cancer",
abstract = "Immunosuppressive acidic protein (IAP) serum levels were determined by single radial immunodiffusion in 180 women with breast cancer, in 33 with benign breast disease and in 66 healthy controls. IAP cut-off value was set at 550 μg/ml (mean for the control group plus 2SD). Higher values were found in 4/48 (8{\%}) women with benign breast disease and in 80/180 (44{\%}) patients (pts) with breast carcinoma considering all stages. In particular, with regard to the stage of disease, elevated IAP levels were observed in 6/50 (12{\%}) pts with negative axillary limphnodes (N-), in 45/95 (47{\%}) pts with positive limphnodes (N+) and in 29/35 (83{\%}) pts with metastatic disease. Among healthy subjects only 2/66 (3{\%}) women showed elevated serum IAP levels. Our preliminary data show that IAP is a reliable tumor marker in advanced breast cancer, therefore it can be useful in monitoring the clinical course of the disease. Moreover it may aid in postoperative follow-up, detecting relapse or metastasis and may be recommended as an addition to diagnostic procedures.",
author = "M. Quaranta and M. Coviello and V. Lorusso and C. Rella and G. Micelli and Torre, {G. C.}",
year = "1990",
language = "English",
volume = "5",
pages = "191--194",
journal = "Journal of Tumor Marker Oncology",
issn = "0886-3849",
publisher = "International Academy of Tumor Marker Oncology",
number = "2",

}

TY - JOUR

T1 - Immunosuppressive acidic protein (IAP) serum levels in breast cancer

AU - Quaranta, M.

AU - Coviello, M.

AU - Lorusso, V.

AU - Rella, C.

AU - Micelli, G.

AU - Torre, G. C.

PY - 1990

Y1 - 1990

N2 - Immunosuppressive acidic protein (IAP) serum levels were determined by single radial immunodiffusion in 180 women with breast cancer, in 33 with benign breast disease and in 66 healthy controls. IAP cut-off value was set at 550 μg/ml (mean for the control group plus 2SD). Higher values were found in 4/48 (8%) women with benign breast disease and in 80/180 (44%) patients (pts) with breast carcinoma considering all stages. In particular, with regard to the stage of disease, elevated IAP levels were observed in 6/50 (12%) pts with negative axillary limphnodes (N-), in 45/95 (47%) pts with positive limphnodes (N+) and in 29/35 (83%) pts with metastatic disease. Among healthy subjects only 2/66 (3%) women showed elevated serum IAP levels. Our preliminary data show that IAP is a reliable tumor marker in advanced breast cancer, therefore it can be useful in monitoring the clinical course of the disease. Moreover it may aid in postoperative follow-up, detecting relapse or metastasis and may be recommended as an addition to diagnostic procedures.

AB - Immunosuppressive acidic protein (IAP) serum levels were determined by single radial immunodiffusion in 180 women with breast cancer, in 33 with benign breast disease and in 66 healthy controls. IAP cut-off value was set at 550 μg/ml (mean for the control group plus 2SD). Higher values were found in 4/48 (8%) women with benign breast disease and in 80/180 (44%) patients (pts) with breast carcinoma considering all stages. In particular, with regard to the stage of disease, elevated IAP levels were observed in 6/50 (12%) pts with negative axillary limphnodes (N-), in 45/95 (47%) pts with positive limphnodes (N+) and in 29/35 (83%) pts with metastatic disease. Among healthy subjects only 2/66 (3%) women showed elevated serum IAP levels. Our preliminary data show that IAP is a reliable tumor marker in advanced breast cancer, therefore it can be useful in monitoring the clinical course of the disease. Moreover it may aid in postoperative follow-up, detecting relapse or metastasis and may be recommended as an addition to diagnostic procedures.

UR - http://www.scopus.com/inward/record.url?scp=0025171587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025171587&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 191

EP - 194

JO - Journal of Tumor Marker Oncology

JF - Journal of Tumor Marker Oncology

SN - 0886-3849

IS - 2

ER -